Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-19T20:18:18.277Z Has data issue: false hasContentIssue false
  • English
  • Français

Pseudomonas aeruginosa Nosocomial Pneumonia: Impact of Pneumonia Classification

Published online by Cambridge University Press:  20 July 2015

Scott T. Micek ,
Marin H. Kollef ,
Antoni Torres ,
Catherine Chen ,
Jordi Rello ,
Jean Chastre ,
Massimo Antonelli ,
Tobias Welte ,
Bernard Clair  and
Helmut Ostermann
...Show all authors
Scott T. Micek*
Affiliation:
St. Louis College of Pharmacy, St. Louis, Missouri
Marin H. Kollef
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
Antoni Torres
Affiliation:
Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona–Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB)–SGR 911–Ciber de Enfermedades Respiratorias (Ciberes) Barcelona, Spain
Catherine Chen
Affiliation:
Washington University School of Medicine, St. Louis, Missouri
Jordi Rello
Affiliation:
Hospital Vall D’Hebron, Barcelona, Spain
Jean Chastre
Affiliation:
Groupe Hospitalier Pitie-Salpetriere, Paris, France
Massimo Antonelli
Affiliation:
Policlinico Universitario A. Gemelli, Rome, Italy
Tobias Welte
Affiliation:
Medizinische Hochschule Hannover, Hannover, Germany
Bernard Clair
Affiliation:
Hôpital Raymond Poincaré, Garches, France
Helmut Ostermann
Affiliation:
University Hospital of Munich, Munich, Germany
Esther Calbo
Affiliation:
Hospital Universitari Mutua de Terrassa, Barcelona, Spain
Richard Wunderink
Affiliation:
Northwestern University Feinberg School of Medicine, Chicago, Illinois
Francesco Menichetti
Affiliation:
Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
Garrett Schramm
Affiliation:
Mayo Clinic, Rochester, Minnesota
Vandana Menon
Affiliation:
Cubist Pharmaceuticals, Lexington, Massachusetts
*
Address correspondence to Scott T. Micek, PharmD, St. Louis College of Pharmacy, 4588 Parkview Pl, St. Louis, Missouri 63110-1088 (scott.micek@stlcop.edu).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

To describe and compare the mortality associated with nosocomial pneumonia due to Pseudomonas aeruginosa (Pa-NP) according to pneumonia classification (community-onset pneumonia [COP], hospital-acquired pneumonia [(HAP], and ventilator-associated pneumonia [VAP]).

DESIGN

We conducted a retrospective cohort study of adults with Pa-NP. We compared mortality for Pa-NP among patients with COP, HAP, and VAP and used logistic regression to identify risk factors for hospital mortality and inappropriate initial antibiotic therapy (IIAT).

SETTING

Twelve acute care hospitals in 5 countries (United States, 3; France, 2; Germany, 2; Italy, 2; and Spain, 3).

PATIENTS/PARTICIPANTS

A total of 742 patients with Pa-NP.

RESULTS

Hospital mortality was greater for those with VAP (41.9%) and HAP (40.1%) compared with COP (24.5%) (P<.001). In multivariate analyses, independent predictors of hospital mortality differed by pneumonia classification (COP: need for mechanical ventilation and intensive care; HAP: multidrug-resistant isolate; VAP: IIAT, increasing age, increasing Charlson comorbidity score, bacteremia, and use of vasopressors). Presence of multidrug resistance was identified as an independent predictor of IIAT for patients with COP and HAP, whereas recent antibiotic administration was protective in patients with VAP.

CONCLUSIONS

Among patients with Pa-NP, pneumonia classification identified patients with different risks for hospital mortality. Specific risk factors for hospital mortality also differed by pneumonia classification and multidrug resistance appeared to be an important risk factor for IIAT. These findings suggest that pneumonia classification for P. aeruginosa identifies patients with different mortality risks and specific risk factors for outcome and IIAT.

Infect Control Hosp Epidemiol 2015;36(10):1190–1197

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 36 , Issue 10 , October 2015 , pp. 1190 - 1197
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.CrossRefGoogle Scholar
2. Kollef, MH, Shorr, A, Tabak, YP, Gupta, V, Liu, LZ, Johannes, RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854–3862.CrossRefGoogle ScholarPubMed
3. Sopena, N, Sabria, M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 2005;127:213–219.Google Scholar
4. Weber, DJ, Rutala, WA, Sickbert-Bennett, EE, Samsa, GP, Brown, V, Niederman, MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007;28:825–831.CrossRefGoogle ScholarPubMed
5. Esperatti, M, Ferrer, M, Theessen, A, et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 2010;182:1533–1539.Google Scholar
6. Wang, CY, Jerng, JS, Chen, KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect 2006;12:63–68.Google Scholar
7. Tumbarello, M, De Pascale, G, Trecarichi, EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013;39:682–692.Google Scholar
8. Chung, DR, Song, JH, Kim, SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011;184:1409–1417.Google Scholar
9. Parker, CM, Kutsogiannis, J, Muscedere, J, et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 2008;23:18–26.Google Scholar
10. Zilberberg, MD, Shorr, AF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med 2013;8:559–563.CrossRefGoogle ScholarPubMed
11. Driscoll, JA, Brody, SL, Kollef, MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67:351–368.CrossRefGoogle ScholarPubMed
12. Crouch Brewer, S, Wunderink, RG, Jones, CB, Leeper, KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa . Chest 1996;109:1019–1029.Google Scholar
13. Kollef, MH, Chastre, J, Clavel, M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012;16:R218.CrossRefGoogle ScholarPubMed
14. Garnacho-Montero, J, Sa-Borges, M, Sole-Violan, J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007;35:1888–1895.CrossRefGoogle ScholarPubMed
15. Micek, ST, Reichley, RM, Kollef, MH. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine (Baltimore) 2011;90:390–395.Google Scholar
16. Magiorakos, AP, Srinivasan, A, Carey, RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–281.CrossRefGoogle ScholarPubMed
17. Kollef, MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008;47:S3–13.Google Scholar
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. Wayne, PA: CLSI, 2009:M100–S19.Google Scholar
19. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, versions 1.3 and 2.0. http://www.eucast.org/clinical_breakpoints/. Accessed August 25, 2014.Google Scholar
20. Micek, ST, Kollef, KE, Reichley, RM, Roubinian, N, Kollef, MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007;51:3568–3573.CrossRefGoogle ScholarPubMed
21. Ewig, S, Welte, T, Chastre, J, Torres, A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010;10:279–287.Google Scholar
22. Vallés, J, Martin-Loeches, I, Torres, A, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med 2014;40:572–581.CrossRefGoogle ScholarPubMed
23. Maruyama, T, Fujisawa, T, Okuno, M, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 2013;57:1373–1383.CrossRefGoogle ScholarPubMed
24. Quartin, AA, Scerpella, EG, Puttagunta, S, Kett, DH. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 2013;13:561.CrossRefGoogle ScholarPubMed
25. Piskin, N, Aydemir, H, Oztoprak, N, et al. Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: risk factors and impact on outcomes. BMC Infect Dis 2012;12:268.Google Scholar
26. Iregui, M, Ward, S, Sherman, G, Fraser, VJ, Kollef, MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262–268.Google Scholar
27. Garnacho-Montero, J, Garcia-Garmendia, JL, Barrero-Almodovar, A, Jimenez-Jimenez, FJ, Perez-Paredes, C, Ortiz-Leyba, C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742–2751.Google Scholar
28. Kumar, A, Roberts, D, Wood, KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–1596.Google Scholar
29. Ferrer, R, Martin-Loeches, I, Phillips, G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014;42:1749–1755.Google Scholar
30. Ferrer, R, Artigas, A, Suarez, D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009;180:861–866.CrossRefGoogle ScholarPubMed
31. Zilberberg, MD, Shorr, AF, Micek, MT, Mody, SH, Kollef, MH. Antimicrobial therapy escalation and hospital mortality among patients with HCAP: a single center experience. Chest 2008;134:963–968.CrossRefGoogle ScholarPubMed
32. Kollef, MH, Morrow, LE, Niederman, MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006;129:1210–1218.CrossRefGoogle ScholarPubMed
33. Zilberberg, MD, Shorr, AF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med 2013;8:559–563.CrossRefGoogle ScholarPubMed
34. Vardakas, KZ, Rafailidis, PI, Konstantelias, AA, Falagas, ME. Predictors of mortality in patients with infections due to multi-drug resistant gram negative bacteria: the study, the patient, the bug or the drug? J Infect 2013;66:401–414.Google Scholar
35. Arancibia, F, Bauer, TT, Ewig, S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849–1858.CrossRefGoogle ScholarPubMed
36. Shindo, Y, Ito, R, Kobayashi, D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013;188:985–995.Google Scholar
37. Shorr, AF, Zilberberg, MD, Reichley, R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012;54:193–198.CrossRefGoogle ScholarPubMed
38. Burnham, CA, Frobel, RA, Herrera, ML, Wickes, BL. Rapid ertapenem susceptibility testing and Klebsiella pneumoniae carbapenemase phenotype detection in Klebsiella pneumoniae isolates by use of automated microscopy of immobilized live bacterial cells. J Clin Microbiol 2014;52:982–986.Google Scholar